CN1027179C - 利用啤酒酵母基因bari分泌异种蛋白的方法 - Google Patents

利用啤酒酵母基因bari分泌异种蛋白的方法 Download PDF

Info

Publication number
CN1027179C
CN1027179C CN86107554A CN86107554A CN1027179C CN 1027179 C CN1027179 C CN 1027179C CN 86107554 A CN86107554 A CN 86107554A CN 86107554 A CN86107554 A CN 86107554A CN 1027179 C CN1027179 C CN 1027179C
Authority
CN
China
Prior art keywords
bar1
gene
plasmid
fragment
promotor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN86107554A
Other languages
English (en)
Chinese (zh)
Other versions
CN86107554A (zh
Inventor
维维安·L·麦凯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of CN86107554A publication Critical patent/CN86107554A/zh
Application granted granted Critical
Publication of CN1027179C publication Critical patent/CN1027179C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C12N9/60—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from yeast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN86107554A 1985-10-25 1986-10-25 利用啤酒酵母基因bari分泌异种蛋白的方法 Expired - Lifetime CN1027179C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US79130585A 1985-10-25 1985-10-25
US791,305 1985-10-25
PCT/US1986/002198 WO1987002670A1 (fr) 1985-10-25 1986-10-20 Procede d'utilisation de bar1 pour la secretion de proteines etrangeres
USPCT/US86/02198 1986-10-20

Publications (2)

Publication Number Publication Date
CN86107554A CN86107554A (zh) 1987-08-26
CN1027179C true CN1027179C (zh) 1994-12-28

Family

ID=25153298

Family Applications (1)

Application Number Title Priority Date Filing Date
CN86107554A Expired - Lifetime CN1027179C (zh) 1985-10-25 1986-10-25 利用啤酒酵母基因bari分泌异种蛋白的方法

Country Status (13)

Country Link
EP (1) EP0243465A1 (fr)
JP (1) JP2523562B2 (fr)
CN (1) CN1027179C (fr)
AU (2) AU6543286A (fr)
CA (1) CA1316133C (fr)
CZ (1) CZ284251B6 (fr)
DK (1) DK320287D0 (fr)
FI (1) FI872801A0 (fr)
HU (1) HU206897B (fr)
IE (1) IE63822B1 (fr)
SK (1) SK776486A3 (fr)
UA (1) UA41863C2 (fr)
WO (1) WO1987002670A1 (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK58285D0 (da) * 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
DE3887425T2 (de) * 1987-10-02 1994-06-23 Zymogenetics Inc BAR1-Sekretions-Signal-Sequenz.
US5206699A (en) * 1988-05-06 1993-04-27 Gersan Establishment Sensing a narrow frequency band of radiation and gemstones
EP0387319B1 (fr) * 1988-07-23 1996-03-06 Delta Biotechnology Limited Sequences conductrices secretoires
WO1991013971A1 (fr) * 1990-03-13 1991-09-19 Hawaii Biotechnology Group, Inc. SYSTEME D'EXPRESSION A $i(NEUROSPORA)
DK82893D0 (da) * 1993-07-08 1993-07-08 Novo Nordisk As Peptid
MX9706974A (es) 1995-03-17 1997-11-29 Novo Nordisk As Endoglucanasas novedosas.
AU710818B2 (en) 1996-03-01 1999-09-30 Novo Nordisk A/S Use of a pharmaceutical composition comprising an appetite-suppressing peptide
AR027509A1 (es) 2000-01-10 2003-04-02 Maxygen Aps Conjugados g-csf
ES2325877T3 (es) 2000-02-11 2009-09-23 Bayer Healthcare Llc Moleculas de tipo factor vii o viia.
EP1366075B1 (fr) 2001-02-27 2009-05-27 Maxygen Aps Nouvelles molecules de type interferon beta
CA2441580A1 (fr) 2001-03-22 2002-10-03 Novo Nordisk Health Care Ag Derives du facteur vii de coagulation
US6534059B2 (en) 2001-06-05 2003-03-18 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
CZ2004427A3 (cs) 2001-09-27 2004-08-18 Novoánordiskáhealthácareáag Polypeptidy lidského koagulačního faktoru VII
EP2392655A3 (fr) 2003-09-09 2012-02-29 Novo Nordisk Health Care AG Polypeptides de facteur VII à coagulation
MX2007012887A (es) 2005-04-18 2007-12-10 Novo Nordisk As Variantes il-21.
EP1917363B1 (fr) 2005-08-16 2011-06-22 Novo Nordisk A/S Procede permettant de realiser des polypeptides d'insuline matures
JP5690047B2 (ja) 2005-09-14 2015-03-25 ノボ ノルディスク ヘルス ケア アーゲー ヒト凝固第ｖｉｉ因子ポリペプチド
CN101501216B (zh) 2006-03-06 2013-10-02 胡玛基因公司 制备重组人凝血酶的方法
KR20090060294A (ko) 2006-09-08 2009-06-11 암브룩스, 인코포레이티드 변형된 인간 혈장 폴리펩티드 또는 Ｆｃ 스캐폴드 및 그의 용도
ES2464282T3 (es) 2006-09-27 2014-06-02 Novo Nordisk A/S Método para preparar polipéptidos de insulina madura
BRPI0810622A2 (pt) 2007-05-02 2020-10-13 Ambrx, Inc. polipeptídeos de interferon beta modificados e seus usos
CN101918026B (zh) 2007-11-20 2016-03-02 Ambrx公司 经修饰胰岛素多肽和其用途
UA103774C2 (uk) 2008-07-23 2013-11-25 Амбркс, Інк. Модифіковані поліпептиди бичачого гранулоцитарного колонієстимулювального фактора (g-csf) та їх застосування
US8349325B2 (en) 2008-12-23 2013-01-08 Abbott Laboratories Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making
WO2010103038A1 (fr) 2009-03-11 2010-09-16 Novo Nordisk A/S Variants de l'interleukine 21 se liant de manière antagoniste au récepteur de l'il-21
CN102712687A (zh) 2009-07-17 2012-10-03 丹麦国家医院 作为补体激活的抑制剂的masp同种型
WO2011067283A1 (fr) 2009-12-01 2011-06-09 Novo Nordisk A/S Nouvelles peptidyl a-hydroxyglycine a-amide lyases
EA201290541A1 (ru) 2009-12-21 2013-05-30 Амбркс, Инк. Модифицированные бычьи соматотропиновые полипептиды и их применение
CN104017063A (zh) 2009-12-21 2014-09-03 Ambrx公司 经过修饰的猪促生长素多肽和其用途
CA2791841C (fr) 2010-03-05 2023-01-03 Rigshospitalet Molecules chimeriques inhibitrices d'activation du complement
US20110229921A1 (en) 2010-03-18 2011-09-22 Abbott Laboratories METHODS OF ASSAYING URINARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (uNGAL) IN THE PROGNOSIS OF CADAVERIC KIDNEY TRANSPLANT FUNCTION IN A PATIENT, INCLUDING A PATIENT DIAGNOSED WITH DELAYED GRAFT FUNCTION (DGF), A METHOD OF ASSAYING uNGAL IN THE ASSESSMENT OF RISK OF DGF IN A PATIENT DIAGNOSED WITH EARLY GRAFT FUNCTION (EGF), AND RELATED KITS
WO2011163558A1 (fr) 2010-06-25 2011-12-29 Abbott Laboratories Matériaux et procédés pour le dosage d'anticorps anti-virus de l'hépatite c (hvc)
MA34521B1 (fr) 2010-08-17 2013-09-02 Ambrx Inc Polypeptides de relaxine modifiés et leurs utilisations
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
US20120115244A1 (en) 2010-11-09 2012-05-10 Abbott Laboratories Materials and methods for immunoassay of pterins
CA2819552C (fr) 2010-12-09 2023-09-26 Institut Pasteur Procede a base de mgmt permettant d'obtenir une expression elevee de proteines recombinees
WO2013083847A2 (fr) 2011-12-09 2013-06-13 Institut Pasteur Immunoessai de dépistage multiplex
US8993248B2 (en) 2011-12-31 2015-03-31 Abbott Laboratories Truncated human vitamin D binding protein and mutation and fusion thereof and related materials and methods of use
SG10201606195UA (en) 2012-02-09 2016-09-29 Var2 Pharmaceuticals Aps Targeting of chondroitin sulfate glycans
JP2015532307A (ja) 2012-10-15 2015-11-09 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 凝固因子ｖｉｉポリペプチド
JP2014128262A (ja) * 2012-11-27 2014-07-10 Kirin Brewery Co Ltd 接合能を持つ酵母細胞株のスクリーニング方法
AU2019263303A1 (en) 2018-05-01 2020-12-24 Ambrx, Inc. A method for optimizing antibody expression
US20210278406A1 (en) 2018-07-13 2021-09-09 Varct Diagnostic Aps Isolation of circulating cells of fetal origin using recombinant malaria protein var2csa
PT3849614T (pt) 2018-09-11 2024-02-28 Ambrx Inc Conjugados de polipeptídeos de interleucina-2 e suas utilizações
JP2022512746A (ja) 2018-10-19 2022-02-07 アンブルックス，インコーポレイテッド インターロイキン－１０ポリペプチド複合体、その二量体、およびそれらの使用
US20220226488A1 (en) 2019-02-12 2022-07-21 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
JP2023517595A (ja) 2020-03-11 2023-04-26 アンブルックス，インコーポレイテッド インターロイキン－２ポリペプチド結合物およびその使用方法
EP4136459A1 (fr) 2020-04-13 2023-02-22 Abbott Laboratories Procédés, complexes et kits pour détecter ou déterminer une quantité d'un anticorps anti-ss-coronavirus dans un échantillon
WO2022031804A1 (fr) 2020-08-04 2022-02-10 Abbott Laboratories Méthodes et kits améliorés pour détecter une protéine sars-cov-2 dans un échantillon
KR20230073200A (ko) 2020-08-20 2023-05-25 암브룩스, 인코포레이티드 항체-tlr 작용제 접합체, 그 방법 및 용도
EP4271998A1 (fr) 2020-12-30 2023-11-08 Abbott Laboratories Procédés pour déterminer un antigène sras-cov-2 et anticorps anti-sras-cov-2 dans un échantillon
JP2024512775A (ja) 2021-04-03 2024-03-19 アンブルックス，インコーポレイテッド 抗ｈｅｒ２抗体薬物コンジュゲート及びその使用
CN115806889A (zh) * 2022-09-28 2023-03-17 山东大学 一种提高基因表达水平的酿酒酵母工程菌及其构建方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4546082A (en) * 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4613572A (en) * 1983-08-15 1986-09-23 Kansas State University Research Foundation Yeast BAR1 gene plasmid
DE3537176C2 (de) * 1984-10-18 1994-06-09 Zymogenetics Inc Gewebeplasminogenaktivator und Verfahren zu seiner Herstellung
JPS61247384A (ja) * 1984-10-18 1986-11-04 チモ−ジエネテイツクス　インコ−ポレ−テツド 酵母中でプラスミノ−ゲン活性化因子を発現する方法

Also Published As

Publication number Publication date
EP0243465A1 (fr) 1987-11-04
HU206897B (en) 1993-01-28
UA41863C2 (uk) 2001-10-15
FI872801A (fi) 1987-06-24
CZ776486A3 (en) 1996-09-11
AU7400391A (en) 1991-07-18
DK320287A (da) 1987-06-23
CA1316133C (fr) 1993-04-13
CN86107554A (zh) 1987-08-26
IE63822B1 (en) 1995-06-14
CZ284251B6 (cs) 1998-10-14
FI872801A0 (fi) 1987-06-24
WO1987002670A1 (fr) 1987-05-07
AU676132B2 (en) 1997-03-06
AU6543286A (en) 1987-05-19
JPS63501614A (ja) 1988-06-23
IE862804L (en) 1987-04-25
SK279041B6 (sk) 1998-06-03
DK320287D0 (da) 1987-06-23
JP2523562B2 (ja) 1996-08-14
HUT43624A (en) 1987-11-30
SK776486A3 (en) 1998-06-03

Similar Documents

Publication Publication Date Title
CN1027179C (zh) 利用啤酒酵母基因bari分泌异种蛋白的方法
CA1340772C (fr) Expression et secretion de proteines heterologues dans une levure au moyen de sequences leader tronquees du facteur alpha
CN1069346C (zh) 用解脂亚罗威阿酵母转化株表达和分泌异源蛋白质
EP0123544A2 (fr) Procédé d'expression de protéines hétérologues dans les levures, vecteurs d'expression et micro-organismes du genre levure à cet effet
EP0123289A2 (fr) Facteur-A et ses signaux de traitement
CN1032367A (zh) 含有指导异源多肽分泌的克鲁维酵母α-因子前导顺序的DAN组建物
KR20070009269A (ko) 재조합단백질 생산용 단백질융합인자 라이브러리 및이로부터 획득된 단백질융합인자
EP3874047B1 (fr) Production de protéines régulées à source de carbone dans une cellule hôte recombinante
US9012367B2 (en) Rapid screening method of translational fusion partners for producing recombinant proteins and translational fusion partners screened therefrom
EP0220689B1 (fr) Méthode permettant l'utilisation de BAR1 pour la sécrétion de protéines étrangères
US7198919B1 (en) Use of alpha factor sequences in yeast expression systems
US20200399325A1 (en) Host cell for producing a protein of interest
CN1302333A (zh) 在酵母中制备目的多肽的方法
JP3732516B2 (ja) タンパク質の製造法
KR100626753B1 (ko) 재조합 단백질 생산용 맞춤형 단백질융합인자의 초고속선별 방법
KR20050076603A (ko) 재조합단백질 생산용 단백질융합인자
EP0188555A1 (fr) Vehicule de clonage de levure
CN1309712A (zh) 在转化的酵母细胞中生产蛋白质的方法
CN1035127A (zh) 小蛭素衍生物
KR20050076139A (ko) 단백질 분비 생산을 유도하는 단백질융합인자

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CX01 Expiry of patent term